Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 1:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypersensitivity, Immediate Clear all
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

NCT02105012
View directory record Official record
Conditions
Asthma
Interventions
BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg, BD MDI 40 µg, Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
41
States / cities
Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 24, 2026, 1:22 PM EDT
Terminated Not applicable Interventional

A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema

NCT01826630
View directory record Official record
Conditions
Eczema, Hand Eczema, Atopic Dermatitis
Interventions
CLn BodyWash, Cetaphil Daily Facial Cleanser
Other
Lead sponsor
Shari L Hand
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gahanna, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Not applicable Interventional

The Breathe Well Program for Adults With Asthma

NCT02761837
View directory record Official record
Conditions
Asthma
Interventions
IVR call/text, Email
Behavioral
Lead sponsor
National Jewish Health
Other
Eligibility
19 Years to 99 Years
Enrollment
14,978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 24, 2026, 1:22 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

NCT04140695
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
51
States / cities
Hoover, Alabama • Tempe, Arizona • Encino, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 24, 2026, 1:22 PM EDT
Terminated Phase 3 Interventional Results available

Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)

NCT05545072
View directory record Official record
Conditions
Allergic Fungal Rhinosinusitis
Interventions
Dupilumab, Placebo, Intranasal Corticosteroid Sprays (INCS)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 2 Interventional

A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis

NCT06923228
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
CGB-500 Ointment with 1% tofacitinib, Ruxolitinib 1.5% Cream QD
Drug
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 24, 2026, 1:22 PM EDT
Withdrawn Not applicable Interventional

Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department

NCT00657228
View directory record Official record
Conditions
Anaphylaxis
Interventions
Intravenous heparin, Saline
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

NCT03903822
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-06700841, Vehicle (Placebo)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 24, 2026, 1:22 PM EDT
Terminated Phase 2 Interventional

Impact of Infant Formula on Resolution of Cow's Milk Allergy

NCT02719405
View directory record Official record
Conditions
Milk Allergy
Interventions
Lactobacillus GG, Extensively Hydrolyzed Casein Formula, Amino Acid Formula
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Up to 120 Days
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 3 Interventional

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

NCT05774639
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Omalizumab Injection, Xolair Prefilled Syringe
Drug
Lead sponsor
Kashiv BioSciences, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 24, 2026, 1:22 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

NCT06868212
View directory record Official record
Conditions
Chronic Spontaneous Urticaria (CSU)
Interventions
Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
132
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

AZMATICS: AZithroMycin/Asthma Trial In Community Settings

NCT00266851
View directory record Official record
Conditions
Asthma
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
5
States / cities
Peoria, Illinois • Kansas City, Kansas • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study of Oral Milk Immunotherapy for Cow's Milk Allergy

NCT00465569
View directory record Official record
Conditions
Milk Hypersensitivity
Interventions
cow's milk powder, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 24, 2026, 1:22 PM EDT
Withdrawn Phase 3 Interventional

Asthma Clinical Research Network (ACRN)

NCT00000577
View directory record Official record
Conditions
Asthma, Lung Diseases
Interventions
Albuterol, Colchicine, Adrenal Cortex Hormones, Adrenergic-Beta Agonists
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2008
U.S. locations
7
States / cities
La Jolla, California • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 4 Interventional

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

NCT06806657
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Garadacimab
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Litchfield Park, Arizona • Bentonville, Arkansas • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 2 Interventional

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

NCT06810050
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
CGB-500 with 0.5% tofacitinib, CGB-500 Ointment with 1% tofacitinib, Vehicle (placebo)
Drug
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
12 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Fremont, California • Manhattan Beach, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Repeated Nasal Challenge in Skin Prick-puncture Negative and Intradermal Positive Dust Mite Allergic Rhinitis Patients

NCT01179282
View directory record Official record
Conditions
ALLERGIC RHINITIS
Interventions
dust mite extract or placebo
Biological
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 24, 2026, 1:22 PM EDT
Active, not recruiting Phase 2 Interventional

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

NCT05509023
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ADX-914, Placebo
Drug
Lead sponsor
Q32 Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
24
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Sep 24, 2026, 1:22 PM EDT
Withdrawn Not applicable Interventional

Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children

NCT02458482
View directory record Official record
Conditions
Asthma
Interventions
AccuPAP, Albuterol and Ipratropium Continuous Nebulizer
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 24, 2026, 1:22 PM EDT
Completed No phase listed Observational

An Observational Study of the Use and Safety of Xolair® During Pregnancy

NCT00373061
View directory record Official record
Conditions
Asthma
Interventions
Xolair®
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 24, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Results available

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma

NCT00139659
View directory record Official record
Conditions
Asthma, Diabetes Mellitus
Interventions
Inhaled Insulin, Subcutaneous Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 77 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
86
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2010 · Synced Sep 24, 2026, 1:22 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Esophageal Absorption in EoE

NCT02314455
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
D-xylose
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Sep 24, 2026, 1:22 PM EDT
Terminated Phase 3 Interventional Results available

Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)

NCT03245840
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Budesonide oral suspension
Drug
Lead sponsor
Shire
Industry
Eligibility
11 Years to 55 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 24, 2026, 1:22 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

NCT02246920
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Fluticasone propionate, Flonase®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years and older
Enrollment
1,474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Sep 24, 2026, 1:22 PM EDT